2019Äê | ¥¤¥Ù¥ó¥È
δÀ´ÐÍÒ½¯Ÿ„“Ôì׿Խ´óѧԺ¥×¥í¥°¥é¥à FM DTSÈںϥ»¥ß¥Ê©` Kevin Eggan,Ph.D ÖvÑݻᣨ11/12é_´ß£©
δÀ´ÐÍÒ½¯Ÿ„“Ôì׿Խ´óѧԺ¥×¥í¥°¥é¥à¤Ç¤Ï¡¢–|±±´óѧ²¡ÔºÅR´²Ñо¿ÍÆßM¥»¥ó¥¿©`¥Ð¥¤¥ª¥Ç¥¶¥¤¥ó²¿éT¡¢–|±±´óѧNeuro Global ¹úëH¹²Í¬´óѧԺ¥×¥í¥°¥é¥à¡¢–|±±Ò½Ñ§»á¤È¹²´ß¤Ç¡¢11ÔÂ12ÈÕ(»ð)¤ËFM DTSÈںϥ»¥ß¥Ê©`¤òé_´ß¤·¤Þ¤¹¡£
¹«é_¥»¥ß¥Ê©`¤Ç¤¹¤Î¤Ç¡¢¤É¤Ê¤¿¤Ç¤â¤´²Î¼Ó¤¤¤¿¤À¤±¤Þ¤¹¡£
¡ù°k±íÑÔÕZ¤ÏÓ¢ÕZ¤Ç¤¹¤¬¡¢ÈÕ±¾ÕZÔU¥¹¥é¥¤¥É¤âÌáʾÓ趨¤Ç¤¹¡£
é_´ß¸ÅÒª
ÈÕ•r£º2019Äê11ÔÂ12ÈÕ£¨»ð£©18:00-19:00
»áˆö£º–|±±´óѧÐÇÁꥥã¥ó¥Ñ¥¹ ÐÇÁꥪ©`¥Ç¥£¥È¥ê¥¢¥à
ÖvŽŸ£ºKevin Eggan, Ph.D.£¨Institute Member and Professor, Broad Institute of Harvard and MIT Department of Stem Cell and Regenerative Biology, Harvard University)
ÑÝî}£º¡¸Validation of therapeutic targets and drug candidates using human stem cell models of nervous system disorders¡¹
ÉêÞz·½·¨
ÏÂÓ›[1]¤«[2]¤Î¤¤¤º¤ì¤«¤Î·½·¨¤Ç¤ªÉꤷÞz¤ß¤¯¤À¤µ¤¤
[1]ÉêÞz¤ß¥Õ¥©©`¥à£ºÉêÞz¤ß¥Õ¥©©`¥à
[2]¥á©`¥ë£ºÏÂÓ›¤òÃ÷Ó›¤ÎÉÏ¡¢¡º11/12Kevin Eggan,Ph.D ÖvÑÝ»á²Î¼ÓÏ£Íû¡»¤Èî}¤·¤Ætakuetsu-asu*crieto.hosp.tohoku.ac.jp£¨*¤ò@¤ËÖä“Q¤¨¤Æ¤¯¤À¤µ¤¤¡££©¤Ø¤´ßB½j¤ò¤ªîŠ¤¤¤¤¤¿¤·¤Þ¤¹¡£
1£©ÊÏÃû?¥Õ¥ê¥¬¥Ê¡¡2£©ËùÊô?ÒÛš¡¡3£©¥á©`¥ë¥¢¥É¥ì¥¹
- Ô”¼š£¨Î´À´ÐÍÒ½¯Ÿ„“Ôì׿Խ´óѧԺ¥×¥í¥°¥é¥à¥¦¥§¥Ö¥µ¥¤¥È£©
- δÀ´ÐÍÒ½¯Ÿ„“Ôì׿Խ´óѧԺ¥×¥í¥°¥é¥à¥¦¥§¥Ö¥µ¥¤¥È
- ¥Ý¥¹¥¿©`
†–¤¤ºÏ¤ï¤»ÏÈ
–|±±´óѧδÀ´ÐÍÒ½¯Ÿ„“Ôì׿Խ´óѧԺ¥×¥í¥°¥é¥àÍÆßMÊÒ
TEL£º022-717-8031
E-mail£ºmirai-takuetsu*grp.tohoku.ac.jp£¨*¤ò@¤ËÖä“Q¤¨¤Æ¤¯¤À¤µ¤¤¡££©